The World Health Organization (WHO) has designated the JN.1 coronavirus strain as a “variant of interest,” indicating a low risk to public health. Despite its ability to evade the immune system and exhibit increased transmissibility, experts have not observed signs of more severe disease associated with this variant.
Initially identified as part of the BA.2.86 lineage, JN.1 has now been recognized as a distinct variant of interest by the WHO. According to Andrew Pekosz, a virologist at the Johns Hopkins Bloomberg School of Public Health, while there may be more cases involving the JN.1 variant, it does not pose a greater risk.
The WHO reassures that current vaccines remain effective in protecting against severe illness and death caused by JN.1 and other circulating COVID-19 variants. This classification aligns with the U.S. Centers for Disease Control and Prevention’s statement that JN.1 constitutes approximately 15% to 29% of cases in the United States as of December 8.
The CDC emphasizes that there is currently no evidence suggesting an increased public health risk associated with JN.1 compared to other variants. Furthermore, updated vaccines are expected to provide continued protection against this variant. First identified in the United States in September, JN.1 has also been recently detected in China with seven reported infections.
